Jakob Dupont

Jakob Dupont brings more than two decades of experience in the field of oncology and other therapeutic areas, in developing therapies and programs dedicated to addressing high unmet medical needs.

Prior to joining Sofinnova, Jakob was previously Global Head of Research & Development (R&D) and Executive Vice President at Atara Biotherapeutics, where he helped lead efforts to secure regulatory approval of the first-in-kind product, Ebvallo, and advancing a multiple sclerosis candidate (ATA188) to a key Phase 2 read out. Prior to Atara, he served as the Chief Medical Officer at Gossamer Bio, overseeing global development, regulatory, and quality activities for the company, and advancing therapeutics in the disease areas of immunology, inflammation, and oncology. Before Gossamer Bio, Jakob served as Vice President and Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche, where he was responsible for the global development of Herceptin, Perjeta, Kadcyla, Tecentriq, among others, and where he previously led the development of Avastin for GYN and Breast Cancers when starting his industry career. Jakob was also Chief Medical Officer and Senior Vice President of OncoMed Pharmaceuticals, Inc., where he oversaw the successful submissions of eight investigational new drug applications (INDs) and 26 clinical trial initiations. Throughout his industry career, he has received numerous grants and awards, contributed to 12 regulatory approvals, 13 successful IND filings, co-authored 47 peer-reviewed publications, and has 18 patents.

Jakob received his M.D. from Joan & Sanford 1. Weill Medical College of Cornell University and his M.A. in philosophy from New York University. He also served as Assistant Chief Resident and completed his Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center (MSK), his Internal Medicine Residency at the New York Presbyterian Hospital, Cornell Campus, and his Internal Medicine Internship at The University of Michigan Medical Center.